Captagon: deconstructing the myth

 

efdallx7.jpg

Drugs, International Challenges n° 10, OFDT, 7 p.
July 2017


Captagon, in the overwhelming majority of cases, aside from the classic "fakes", is now simply another "street name" for amphetamine or speed. This relatively commonplace substance was, until the 2000s, manufactured by Balkan, Bulgarian and Turkish networks, specialising in the synthesis of amphetamine and its transformation into tablets. Owing to law enforcement actions, part of production appears to have relocated closer to consumer markets in the Persian Gulf, and to Lebanon in particular, as shown by combined seizures of precursors, amphetamine and captagon tablets. This must be understood in the context of armed violence in the Middle East, with the outbreak of the Syrian Civil War and the break-up of Iraq, notably due to the activities of the jihadi armies. These combined events have helped sustain a series of rumours and allegations. The one often rehearsed in the media, that "commonplace" captagon is the "jihadi drug", the substance preferred by Daesh terrorists, especially in France, has been refuted by objective findings, and will remain mere speculation until proven otherwise.

Author: Laurent Laniel

Download the PDF file (1,1 Mo)

 

 

 

 

 

 

 

 

 

 

Drugs in Europe


2017 EMCDDA European Drug Report

miniEDR2017EN.jpgWhat do the latest data tell us about the European drug market? What are the new trends in drug use among European adults and school students? What are the harms associated with drug use and what is being done to counter them? These and other questions are explored in the 2017 EMCDDA European Drug Report.

  Country drug reports 2017

miniCountryProfiles.jpgDeveloped by the EMCDDA, in cooperation with the Reitox national focal points, these graphic-rich reports cover: drug use and public health problems; drug policy and responses and drug supply.

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.